title: Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.
abstract: Echinocandins are approved for the treatment of candidal infections. In vitro they have been shown to be less potent against strains of Candida parapsilosis than against other Candida spp. This is the first case report describing the development of a secondary multidrug (echinocandin-azole)-resistant Candida strain during therapy.
authors.affiliation: Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA.
authors.forename: Varsha
authors.initials: V
authors.lastname: Moudgal
authors.forename: Tania
authors.initials: T
authors.lastname: Little
authors.forename: Dina
authors.initials: D
authors.lastname: Boikov
authors.forename: Jose A
authors.initials: JA
authors.lastname: Vazquez
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects* / Q000235:genetics; D000077336:Caspofungin; D026141:Drug Resistance, Multiple, Fungal; D054714:Echinocandins; D004586:Electrophoresis; D004696:Endocarditis / Q000188:drug therapy / Q000382:microbiology*; D005838:Genotype; D006350:Heart Valve Prosthesis / Q000382:microbiology*; D006801:Humans; D007621:Karyotyping; D055666:Lipopeptides; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000494:pharmacology*; D016459:Prosthesis-Related Infections / Q000382:microbiology*; D012008:Recurrence
chemical_list: D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000077336:Caspofungin